India, March 19 -- The RADIANT trial conducted by Insulet Corp. (PODD) highlighted significant glycemic improvements with the use of the Omnipod 5 Automated Insulin Delivery System. These improvements were observed following a direct transition from multiple daily injections.
The company said the RADIANT study is the first randomized controlled trial to evaluate the direct transition from multiple daily injections (MDI) to an automated insulin delivery (AID) system in adults and children with type 1 diabetes, as well as being the first to assess the safety and efficacy of an AID system paired with an Abbott FreeStyle Libre 2 family sensor.
The study found that for adults and children not previously meeting clinical targets for HbA1c on mu...